Brain HealthOral GLP-1 Drug Crosses Blood-Brain Barrier to Reverse Alzheimer's Metabolism
Researchers developed OHP2, an oral GLP-1 receptor agonist that can cross the blood-brain barrier — something existing GLP-1 drugs struggle to do. Once inside the brain, OHP2 activates receptors on astrocytes, the brain's support cells, triggering increased sugar burning and lactate production. This lactate is then shuttled into neurons, where it triggers a molecular switch that promotes the transfer of fats back to astrocytes for processing. This back-and-forth metabolic loop between astrocytes and neurons is disrupted in Alzheimer's disease. By restoring it, OHP2 corrects the energy and lipid imbalances that drive neurodegeneration. The findings suggest that activating GLP-1 receptors directly in the brain — not just in the body — may be a powerful and previously underexplored strategy for treating Alzheimer's disease.
